Evidence map›Paper›PMID 42512015›Full record

ReviewBiomedicines2026

Hepatitis C in the Direct-Acting Antiviral Era: Immunopathogenesis, Dendritic Cells and Modern Clinical Management.

Klara Kurmangaliyeva, Bakhyt Kosherova, Irina Mukatova, Aida Baibusunova, Zhanna Yeshmagambetova, Karashash Askarova, Assem Kazangapova, Raikhan Shlymova

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomedicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Klara KurmangaliyevaDepartment of Internal Diseases No. 3, Astana Medical University, Astana 010000, Kazakhstan.
Bakhyt KosherovaSchool of Medicine, Karaganda Medical University, Karaganda 100000, Kazakhstan.
Irina MukatovaDepartment of Internal Diseases No. 3, Astana Medical University, Astana 010000, Kazakhstan.
Aida BaibusunovaDepartment of Internal Diseases No. 3, Astana Medical University, Astana 010000, Kazakhstan.
Zhanna YeshmagambetovaDepartment of Internal Diseases No. 3, Astana Medical University, Astana 010000, Kazakhstan.
Karashash AskarovaDepartment of Internal Diseases No. 2, Astana Medical University, Astana 010000, Kazakhstan.
Assem KazangapovaDepartment of Internal Diseases No. 3, Astana Medical University, Astana 010000, Kazakhstan.ORCID 0000-0002-7676-8310
Raikhan ShlymovaDepartment of Internal Diseases No. 3, Astana Medical University, Astana 010000, Kazakhstan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis C virus (HCV) infection remains a major cause of chronic liver disease worldwide, with potential progression to advanced fibrosis, cirrhosis, hepatocellular carcinoma, and extrahepatic disease. According to World Health Organization estimates, approximately 50 million people worldwide live with chronic HCV infection, and nearly 1 million new infections occur each year. In 2022, approximately 242,000 deaths were attributed to hepatitis C, mainly from cirrhosis and hepatocellular carcinoma. Chronic infection develops when antiviral immune response fails to eliminate the virus. Viral clearance requires early innate immune activation, effective antigen presentation, broad HCV-specific CD4

Indexed as

dendritic cellsdirect-acting antiviralsHCV RNAhepatitis Chepatitis C virusplasmacytoid dendritic cellsresistance-associated substitutionssustained virologic response

Identifiers

PMID42512015
PMCPMC13406076

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.